Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Array, VentiRx Enter License Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Array, VentiRx Enter License Agreement

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Array BioPharma and VentiRx Pharmaceuticals have entered into a license agreement granting VentiRx exclusive worldwide rights to Array’s Toll-like receptor (TLR) program. The program contains development candidates targeting TLRs to activate innate immunity. VentiRx expects to develop its first two candidates in oncology and allergy.

Array will receive an equity stake in VentiRx as well as an upfront payment, potential milestone payments and royalties on product sales. Array retains the option to acquire a 50% ownership position in all VentiRx clinical oncology products developed under this agreement. Financial details of the agreement were not disclosed.

“These novel small molecule compounds from Array represent a significant opportunity for VentiRx and are ideally suited for our core competencies,” said Michael Kamdar, executive vice president and chief business officer at VentiRx. “This licensing agreement, coupled with our $28.9 million financing, puts us in a strong position to develop novel TLR-based therapeutics.”

“We believe VentiRx is a strong partner for developing this program based on their extensive background and focus on innate immunity,” said David Snitman, Ph.D., chief operating officer, Array BioPharma. “As Array continues to progress its clinical pipeline of small molecule therapeutic products, we will look for novel opportunities, such as this licensing agreement with VentiRx, to maximize the value of our preclinical assets.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters